BofA Global Research cuts Madrigal Pharmaceuticals price objective to $533 from $543
MDGL•BofA Global Research cut its price objective for Madrigal Pharmaceuticals to $533 from $543.
Related News
Immunic expects funding to last into late 2027
IMUX•
Aramark schedules fourth-quarter and full-year results call
ARMK•
Indian bonds give up day's gains as oil price spike adds to rate hike fears
TLT•
Red Rock Resorts, Inc.: Morgan Stanley cuts target price to $59 from $61
RRR•
Fifth Third Bancorp outlook: Q4 NII up 2.5%-3.5%
FITB•